Selecta Biosciences (SELB) Misses Q2 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500, Nasdaq set for higher open as investors weigh weaker oil, PPI data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
August 6, 2020 7:30 AM EDTClosed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in potential milestones, and tiered double-digit royaltiesEntered into research license and option agreement with Sarepta for the use of the ImmTOR immune tolerance platform in Sareptas gene therapy programs in certain neuromuscular diseasesGene therapy program in MMA in collaboration with AskBio on track to enter the clinic in the first half of 2021; preliminary data expected in the second half of 2021Phase 3 clinical program of SEL-212 to commence with Sobi in Q3 2020; on track to... More
